Global Ganja Report

Justin Cooper is co-founder and CEO of British Columbia-based Green Planet, which supplies equipment to all of Canada's Licensed Producers of cannabis as well as producing its own line of fertilizers. He speaks with Cannabis Now about the fast-growing legal industry in his country, and what it means for the world.

As legal cannabis finally becomes a reality in Canada, a policy patchwork across the country's provinces and ongoing political tussles have left many confused as to what the new system will actually look like. We break down some of the frequently asked questions. 

A growing number among Canada's First Nations are looking to legal cannabis as a path to economic empowerment. Others are deeply skeptical, recalling the bitter history of substance abuse among Canada's indigenous communities. Yet all seem united in demanding sovereign control on the cannabis question within their own reserves.

Over the past two years, the Latin American cannabis industry has "emerged from the shadows" to command the attention of international firms and investors. Legal cannabis sales within the region are on track to reach $125 million in 2018—but that figure is expected to rise to $12.7 billion by 2028.

A legal medical marijuana export industry is coming to Jamaica, which has just dispatched its first shipment of cannabis oil to Canada. Long famous for its contraband product, the island nation now has a Cannabis Licensing Authority to oversee legal cultivation.

After years of upholding employee firings for use of cannabis even under state medical marijuana programs, the courts are finally starting to turn around on the question.

One of the ways state medical marijuana programs have failed to fully extend protection to medicinal users is in failure to defend against employment discrimination. This is now beginning to change, thanks to a few recent court decisions in favor of patients and employees.

The woman behind the South American nation's new medical marijuana law may yet face prison time. Her crime? Providing the only medicine that worked for her ailing son.

In the working-class Lima district of Pueblo Libre, I make my way to an apartment complex and up to the flat of Ana Álvarez—the unlikely woman almost singly responsible for Peru’s groundbreaking new medical marijuana law.

In a bedroom, 18-year-old Anthony watches a noisy Spiderman movie, occasionally interrupting through the open door as I chat with his mom in the living room. Anthony suffers from tuberous sclerosis, a severe form of epilepsy, and was the voiceless central figure behind the events that led to a major reform of Peru’s drug laws in 2017.

Last month, the DEA enthused the pharmaceutical industry but disappointed cannabis advocates by re-scheduling the drug Epidiolex—but not CBD, the cannabinoid that makes it work. Now word emerges of a letter to the DEA by the Food & Drug Administration essentially calling for the descheduling of CBD altogether.